IV Fluid Shortages — Economics, Capacity, and the Role of Resiliency Standards
|
When IV fluid shortages occur, a familiar narrative follows: “The system is fragile.” These reactions are understandable. |
 |
IV fluids are foundational to clinical care. Shortages are visible, disruptive, and consequential.
But attributing these events primarily to operational incompetence or governance failure overlooks important structural characteristics of the market.
A significant component of the explanation is economic.
What the System Actually Looks Like
The U.S. IV fluid market includes:
|
Multiple manufacturers |
|---|
|
Production facilities across several regions |
|
Continuous, 24/7 manufacturing operations |
|
Mature FDA oversight |
|
Highly optimized, capital-intensive production platforms |
Under steady-state conditions, performance reliability is high. Routine disruptions are typically absorbed through hospital inventory buffers, sourcing diversification strategies, and standard contingency protocols.
In normal operating environments, the system performs.
The vulnerability appears under extreme stress.
Where Shortages Emerge
Major IV fluid shortages tend to follow low-frequency, high-severity disruption — often natural disasters that disable a high-output production site.
When a large-scale facility is compromised:
This dynamic is less a governance failure than a reflection of capacity utilization realities.
IV fluids are low- or near-zero-margin products. Facilities are engineered for efficiency and sustained throughput — not idle surge. Maintaining large volumes of unused manufacturing capacity would require:
Current reimbursement structures generally do not fund that level of overcapacity
The system is optimized for efficiency — not for catastrophic redundancy.
The Economic Question
Achieving disaster-level resilience that mirrors steady-state reliability would require intentional, funded excess capacity.
That raises a straightforward question:
Who is willing to pay for that insurance premium?
Absent reimbursement reform, mandated capacity incentives, guaranteed purchasing agreements, or structured public–private funding mechanisms, rational firms will optimize for efficiency rather than idle surge.
This is not negligence.
It is capital allocation logic.
Why Inventory Is Often the Default Response
In response to shortages, healthcare systems and public entities often increase local inventory buffers.
Inventory appears actionable. It is visible, administratively straightforward, and avoids structural reimbursement reform.
But inventory has inherent constraints:
Inventory smooths short-term volatility.
It does not replace manufacturing capacity during prolonged disruption.
Where Resiliency Standards Fit
It is important to separate two distinct issues:
|
The economic design of surge capacity |
|---|
|
The operational maturity of organizations operating within that design |
Resiliency standards do not create new factories.
They do not install excess capacity.
They do not change reimbursement economics.
What they evaluate is governance maturity.
The HIRC Resiliency Badge assesses whether suppliers have embedded, enterprise-wide capability to:
In a structurally lean system, governance discipline materially influences how disruption unfolds.
Resiliency maturity does not eliminate supply shock.
It improves response, predictability, and recovery performance within economic constraints.
What Standards Do — and Do Not — Address
Clarity about scope is essential.
Resiliency standards:
They do not:
There is no contradiction between suppliers demonstrating high resiliency maturity and the system experiencing shortages during extreme events.
The remaining vulnerability appears more closely tied to economic structure than to governance defect alone.
It is an economic structure decision.
The Real Path Forward
If near-perfect disaster-level reliability is deemed necessary for low-margin medical commodities, the funding mechanism must be addressed directly.
Potential approaches could include:
Until such mechanisms are implemented, the system will continue to operate at high efficiency and high steady-state reliability — without built-in catastrophic overcapacity.
In that environment, governance maturity becomes even more important.
Standards do not change the economic ceiling. They raise the performance floor.
And in a structurally lean system, that distinction matters.
